title: [Relationship between expression of anaplastic lymphoma kinase in pleural effusion and clinicopathological features of patients with lung adenocarcinoma and the response to crizotinib].
abstract: OBJECTIVE
  To explore the expression of anaplastic lymphoma kinase (ALK) protein in pleural effusion cells from patients with lung adenocarcinoma and to investigate the relationship between ALK status and the clinicopathological features, and the response to crizotinib.
  
  
  METHODS
  Eighty-five cases were reviewed from Sept. 2013-Nov. 2014 at Beijing Chest Hospital. There were 42 males and 43 females, with a median age of 58 (30-87). ALK rearrangements were screened by using immunohistochemistry on Benchmark XT auto-stainer.
  
  
  RESULTS
  The frequency of ALK positive reactivity was 15.3% among the 85 patients. The incidence of ALK expression was more frequent in patients <60 years as compared with patients ≥ 60 years of age (26.1%, 2.6%, χ² =9.015, P=0.002). Among the ALK-positive patients, 8 were males and 5 were females (19.1%, 11.6%, χ² =0.903, P=0.259). There were 8 never-smokers and 5 smokers harboring ALK rearrangement (17.0%, 13.5%, χ²=0.379, P=0.827). Among patients with ALK rearrangement, 6 received EGFR detection, and 5 showed no EGFR mutation, and 1 showed 19del EGFR mutation. Among the 13 ALK-positive patients, 4 received crizotinib therapy, and all showed partial response.
  
  
  CONCLUSIONS
  Patients with lung adenocarcinoma with ALK rearrangement were significantly younger than those with ALK wild-type, and ALK rearrangement was rarely concur with EGFR mutation. Screening ALK fusion protein expression in patients with lung adenocarcinoma by paraffin-embedded sediments of pleural effusion was useful in guide of crizotinib therapy.
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Mu
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Qu
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Zhao
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Yujie
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Chongli
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Pathology, Beijing Chest Hospital, Capital Medical University; Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China; Email: zhqing56@sina.com.
authors.forename: Haiqing
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077548:Anaplastic Lymphoma Kinase; D000068476:Beijing; D000077547:Crizotinib; D005260:Female; D006801:Humans; D008175:Lung Neoplasms; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010996:Pleural Effusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D020794:Receptor Protein-Tyrosine Kinases
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases